Progress towards a vaccine for Huntington's disease

Molecular Therapy

Volumn 7, Issue 5, 2003, Pages 569-570

  Luthi Carter, Ruth ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; COMPLEMENTARY DNA; DNA VACCINE; GREEN FLUORESCENT PROTEIN; HUNTINGTIN; INSULIN; POLYGLUTAMINE; PROTEIN ANTIBODY;

ALZHEIMER DISEASE; ANTIBODY TITER; ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEVELOPMENTAL DISORDER; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENCEPHALITIS; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; IMMUNIZATION; IMMUNOTHERAPY; INSULIN DEFICIENCY; LYMPHOCYTIC INFILTRATION; MENTAL DISEASE; MOTOR DYSFUNCTION; MOUSE; NONHUMAN; PATHOGENESIS; PLASMID; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENIC MOUSE; TREATMENT OUTCOME; TRINUCLEOTIDE REPEAT; VACCINATION; VACCINE PRODUCTION;

MUS MUSCULUS;

EID: 0038529728     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1525-0016(03)00107-2     Document Type: Article

References (9)

1. Young, A. B. (2003). Huntingtin in health and disease. J. Clin. Invest. 111: 299-302.
2. Miller, T. W. et al. (2003). DNA Vaccination against mutant huntington ameliorates the HDR6/2 diabetic phenotype. Mol. Ther., this issue
3. Lecerf, J. -M., et al. (2001). Human single-chain Fv intrabodies counteract in situ huningtin aggregation in cellular models of Huntington's disease. Proc. Natl. Acad. Sci. USA 98: 4764-4769.
4. Khoshnan, A. et al. (2002). Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc. Natl. Acad. Sci. USA 99: 1002-1007.
5. Krieg, A. M. (2002). CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20: 709-760.
6. Weiner, H. L. and Selkoe, D. J. (2002). Inflammation and therapeutic vaccination in CNS diseases. Nature 420: 879-884.
7. Shenk, D. (2002). Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. Neurosci. 3: 825-828.
8. Ubol, S. et al. (1995). Roles of immunoglobulin valency and the heavy-chain constant domain in antibody-mediated downregulation of Sindbis virus replication in persistently infected neurons. J. Virol. 69: 1990-1993.
9. Nicoll, J. A. R., et al. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med. 9, advance online publication doi:10.1038/nm840.